Publications by authors named "D Kampik"
Introduction: Small fiber pathology may be involved in the pathophysiology of pain in women with fibromyalgia syndrome (FMS).
Objectives: This prospective single-center case-control study provides detailed pain phenotyping and small fiber pathology data in a cohort of men with FMS on a morphological and functional level.
Methods: Forty-two men with FMS underwent a comprehensive pain-related interview and neurological examination, a questionnaire and neurophysiological assessment, and specialized small fiber tests: skin punch biopsy, quantitative sensory testing including C-tactile afferents, and corneal confocal microscopy.
The use of intraluminal PRESERFLO stenting in avoiding early postoperative hypotony.
Graefes Arch Clin Exp Ophthalmol
December 2024
Purpose: Postoperative hypotony following PRESERFLO MicroShunt (PMS) implantation is a frequent cause of complications such as choroidal detachment and hypotony maculopathy. This study aims at evaluating the impact of intraluminal stenting of the PMS during the early postoperative period.
Methods: We retrospectively analyzed the data of 97 patients who underwent PMS implantation with intraoperative placement of a Nylon 10-0 suture as intraluminal stent (PStent) and compared the outcomes to those of an existing database of the traditional MicroShunt implantation technique (PTrad, n = 120).
Article Synopsis
- Belantamab mafodotin is an innovative drug approved for treating multiple myeloma patients who have not responded to other therapies, providing an alternative for those who can't use CAR-T or bispecific antibodies.
- The drug's unique ocular side effects, like corneal microcysts and keratopathy, pose challenges for broader usage, and the study identifies a possible mechanism through which the drug affects the eyes via soluble BCMA (sBCMA) in tear fluid.
- Results show that inhibiting the uptake of sBCMA could prevent keratopathy, suggesting that future treatment strategies might involve using different therapies before administering belantamab or combining it with gamma-secretase inhibitors in ongoing research.